<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372735</url>
  </required_header>
  <id_info>
    <org_study_id>NEOPANC</org_study_id>
    <nct_id>NCT01372735</nct_id>
  </id_info>
  <brief_title>Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer</brief_title>
  <acronym>NEOPANC</acronym>
  <official_title>Clinical Phase I/II Trial to Investigate Neoadjuvant Intensity-Modulated Short Term Radiation Therapy (5x5 Gy) and Intraoperative Radiation Therapy (15 Gy) in Patients With Primarily Resectable Pancreatic Cancer - NEOPANC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard treatment for patients with primarily resectable pancreatic tumors&#xD;
      consists of surgery followed by adjuvant chemotherapy. But even in this prognostic favourable&#xD;
      group, long term survival is disappointing because of high local and distant failure rates.&#xD;
      Postoperative chemoradiation has shown improved local control and overall survival compared&#xD;
      to surgery alone but the value of additional radiation has been questioned in case of&#xD;
      adjuvant chemotherapy. However, there remains a strong rationale for the addition of&#xD;
      radiation therapy considering the high rates of microscopically incomplete resections after&#xD;
      surgery. As postoperative administration of radiation therapy has some general disadvantages,&#xD;
      neoadjuvant and intraoperative approaches theoretically offer benefits in terms of dose&#xD;
      escalation, reduction of toxicity and patients comfort especially if hypofractionated&#xD;
      regimens with highly conformal techniques like intensity-modulated radiation therapy are&#xD;
      considered.&#xD;
&#xD;
      Therefore the NEOPANC trial has been designed as a prospective, one armed single center study&#xD;
      to investigate a combination of neoadjuvant short course intensity-modulated radiation&#xD;
      therapy (5x5 Gy) in combination with surgery and intraoperative radiation therapy (15 Gy)&#xD;
      followed by adjuvant chemotherapy according to german treatment guidelines in patients with&#xD;
      primarily resectable pancreatic cancer. The primary objectives of the NEOPANC trial are to&#xD;
      evaluate the general feasibility of this approach and the local recurrence rate after one&#xD;
      year. Secondary endpoints are progression-free survival, overall survival, acute and late&#xD;
      toxicity, postoperative morbidity and mortality and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 5 years from first day of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years from first day of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant short course IMRT</intervention_name>
    <description>neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IORT</intervention_name>
    <description>intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  histologically confirmed, primary pancreatic cancer of the pancreatic head&#xD;
&#xD;
          -  judged as gross completely resectable&#xD;
&#xD;
          -  absence of lymph node metastases at the splenic hilum or along the pancreatic tail&#xD;
&#xD;
          -  no evidence of distant metastases&#xD;
&#xD;
          -  age &gt; 50 years&#xD;
&#xD;
          -  Karnofsky performance score ≥ 70%&#xD;
&#xD;
          -  adequate bone marrow function (neutrophils &gt; 2000/µl, platelets &gt; 100000/µl)&#xD;
&#xD;
          -  adequate renal function (Creatinine &lt; 1.5 mg/dl)&#xD;
&#xD;
          -  adequate liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  missing written informed consent&#xD;
&#xD;
          -  missing histological conformation of pancreatic cancer&#xD;
&#xD;
          -  judged as gross incomplete or not resectable&#xD;
&#xD;
          -  pancreatic cancer located in the pancreatic corpus or tail&#xD;
&#xD;
          -  recurrent pancreatic cancer&#xD;
&#xD;
          -  incomplete staging&#xD;
&#xD;
          -  presence of lymph node metastases along the pancreatic tail or splenic hilum&#xD;
&#xD;
          -  presence of distant metastases&#xD;
&#xD;
          -  prior radiation therapy to the upper abdominal region&#xD;
&#xD;
          -  neoadjuvant chemotherapy or immunotherapy&#xD;
&#xD;
          -  participation in another clinical interventional study&#xD;
&#xD;
          -  age ≤ 50 years&#xD;
&#xD;
          -  other previous or active malignancy (excluding basal cell carcinoma, carcinoma in situ&#xD;
             of the cervix)&#xD;
&#xD;
          -  Karnofsky performance score &lt;70%&#xD;
&#xD;
          -  inadequate bone marrow function&#xD;
&#xD;
          -  inadequate renal or liver function&#xD;
&#xD;
          -  any other disease or situation, which generally prohibits the use of major surgery or&#xD;
             radiation therapy according to the judgement of a surgeon or radiation oncologist&#xD;
&#xD;
          -  inability to participate in regular follow up&#xD;
&#xD;
          -  pregnancy, inability or incompliance for adequate contraception&#xD;
&#xD;
          -  missing ability to give informed consent&#xD;
&#xD;
          -  legal custody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Falk FF Roeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter E Huber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, German Cancer Research Center (DKFZ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Werner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, University Hospital of Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Falk FF Roeder, MD</last_name>
    <phone>+4962215639587</phone>
    <email>Falk.Roeder@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter E Huber, MD, PhD</last_name>
    <phone>+496221422515</phone>
    <email>P.Huber@dkfz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, German Cancer Research Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter E Huber, MD, PhD</last_name>
      <phone>+496221422515</phone>
      <email>P.Huber@dkfz.de</email>
    </contact>
    <investigator>
      <last_name>Peter E Huber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Timke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Falk FF Roeder, MD</last_name>
      <phone>+4962215639587</phone>
      <email>Falk.Roeder@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Falk FF Roeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Debus, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jens Werner, MD</last_name>
      <phone>+4962215639692</phone>
      <email>Jens.Werner@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jens Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus W Buechler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutz Schneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <last_update_submitted>June 10, 2011</last_update_submitted>
  <last_update_submitted_qc>June 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Falk Roeder</name_title>
    <organization>Department of Radiation Oncology, University of Heidelberg</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>intensity-modulated radiation therapy</keyword>
  <keyword>intraoperative radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

